A detailed history of State Street Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,361,178 shares of JANX stock, worth $83.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,361,178
Previous 1,401,234 2.86%
Holding current value
$83.8 Million
Previous $58.7 Million 5.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $1.41 Million - $2.01 Million
-40,056 Reduced 2.86%
1,361,178 $61.8 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $35.2 Million - $64.9 Million
1,001,767 Added 250.78%
1,401,234 $58.7 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $411,424 - $2.58 Million
51,882 Added 14.93%
399,467 $15 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $93,681 - $187,363
16,014 Added 4.83%
347,585 $3.73 Million
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $9,741 - $14,266
-1,019 Reduced 0.31%
331,571 $3.34 Million
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $376,287 - $540,659
33,961 Added 11.37%
332,590 $3.95 Million
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $174,588 - $344,676
15,519 Added 5.48%
298,629 $3.61 Million
Q4 2022

Feb 14, 2023

BUY
$11.1 - $18.26 $209,823 - $345,168
18,903 Added 7.15%
283,110 $3.73 Million
Q3 2022

Nov 15, 2022

BUY
$10.82 - $16.84 $2,001 - $3,115
185 Added 0.07%
264,207 $3.58 Million
Q2 2022

Aug 15, 2022

BUY
$9.52 - $15.65 $209,668 - $344,675
22,024 Added 9.1%
264,022 $3.22 Million
Q1 2022

May 16, 2022

BUY
$13.24 - $20.24 $402,919 - $615,943
30,432 Added 14.38%
241,998 $3.47 Million
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $570,075 - $1.01 Million
36,922 Added 21.14%
211,566 $4.17 Million
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $3.62 Million - $6.06 Million
174,644 New
174,644 $3.78 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.56B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.